# FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer

> **NCT00559377** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 16 (actual)

## Conditions studied

- Cervical Adenocarcinoma
- Cervical Squamous Cell Carcinoma
- Stage IB Cervical Cancer
- Stage IIA Cervical Cancer
- Stage IIB Cervical Cancer
- Stage III Cervical Cancer
- Stage IVA Cervical Cancer
- Stage IVB Cervical Cancer

## Interventions

- **OTHER:** 18F-fluoromisonidazole
- **RADIATION:** fluorodeoxyglucose F 18
- **PROCEDURE:** positron emission tomography
- **OTHER:** tissue oxygen measurement

## Key facts

- **NCT ID:** NCT00559377
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2012-07
- **Final completion:** 2014-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2016-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00559377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00559377, "FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00559377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*